Similarities and differences in peripheral itch and pain pathways in atopic dermatitis
Journal of Allergy and Clinical Immunology · 2024-04 · 153 (4) · 904-912
DOI: 10.1016/j.jaci.2023.10.034 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Allergy and Clinical Immunology, 2024-04. Verfasst von Gil Yosipovitch und 8 weiteren Autor:innen. Beteiligte Einrichtung: Miami Itch Center, Miller School of Medicine, University of Miami, Miami, Fla. Electronic address: yosipog@gmail.com. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc.
Abstract (Originalsprache)
Atopic dermatitis (AD) is predominantly characterized by intense itching, but concomitant skin pain is experienced by more than 40% of patients. Patients with AD display considerable somatosensory aberrations, including increased nerve sensitivity to itch stimuli (hyperknesis), perception of itch from innocuous stimuli (alloknesis), or perception of pain from innocuous stimuli (allodynia). This review summarizes the current understanding of the similarities and differences in the peripheral mechanisms underlying itch and pain in AD. These distinct yet reciprocal sensations share many similarities in the peripheral nervous system, including common mediators (such as serotonin, endothelin-1, IL-33, and thymic stromal lymphopoietin), receptors (such as members of the G protein-coupled receptor family and Toll-like receptors), and ion channels for signal transduction (such as certain members of the transient receptor potential [TRP] cation channels). Itch-responding neurons are also sensitive to pain stimuli. However, there are distinct differences between itch and pain signaling. For example, specific immune responses are associated with pain (type 1 and/or type 3 cytokines and certain chemokine C-C [CCL2, CCL5] and C-X-C [CXCL] motif ligands) and itch (type 2 cytokines, including IL-31, and periostin). The TRP melastatin channels TRPM2 and TRPM3 have a role in pain but no known role in itch. Activation of μ-opioid receptors is known to alleviate pain but exacerbate itch. Understanding the connection between itch and pain mechanisms may offer new insights into the treatment of chronic pain and itch in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Miami Itch Center, Miller School of Medicine, University of Miami, Miami, Fla. Electronic address: yosipog@gmail.com.
- Center for the Study of Itch and Sensory Disorders, Washington University School of Medicine, St Louis, Mo.
- University Hospital Münster, Münster, Germany.
- Massachusetts General Hospital, Charlestown, Mass.
- Institute of Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
- Pfizer Pharmaceuticals Israel Ltd, Herzliya Pituach, Israel.
Förderung
- Pfizer Inc
Zitieren
APA
Yosipovitch, G., Kim, B., Luger, T., Lerner, E., Metz, M., Adiri, R., Canosa, J. M., Cha, A., & Ständer, S. (2024). Similarities and differences in peripheral itch and pain pathways in atopic dermatitis. Journal of Allergy and Clinical Immunology, 153(4), 904-912. https://doi.org/10.1016/j.jaci.2023.10.034
Vancouver
Yosipovitch G, Kim B, Luger T, Lerner E, Metz M, Adiri R, et al. Similarities and differences in peripheral itch and pain pathways in atopic dermatitis. Journal of Allergy and Clinical Immunology. 2024;153(4):904-912. doi:10.1016/j.jaci.2023.10.034
BibTeX
@article{Yosipovitch2024,
author = {Yosipovitch, Gil and Kim, Brian and Luger, Thomas and Lerner, Ethan and Metz, Martin and Adiri, Roni and Canosa, Juliana M and Cha, Amy and Ständer, Sonja},
title = {Similarities and differences in peripheral itch and pain pathways in atopic dermatitis},
journal = {Journal of Allergy and Clinical Immunology},
year = {2024},
volume = {153},
number = {4},
pages = {904--912},
doi = {10.1016/j.jaci.2023.10.034}
}
EUVIMED